Call Us: (1) 608 441-2729 - Email Us info@flugen.com
Twitter
M2SR: The Vaccine
Influenza
Leadership
Executive Team
Board of Directors
Clinical Advisory Board
Investors
News
Contact
Contact
Careers
News
News and opinions
FluGen’s M2SR Phase 2 Human Challenge Trial Initial Results
February 12, 2019
Maggie Coluccy
Influenza
Print Article
FluGen Topline Challenge Results Feb 2019
Download
Share this Story
Facebook
Twitter
LinkedIn
Reddit
Digg
Delicious
Google++
E-Mail+
Comments are closed.
Prev Post
Next Post
Recent News
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
Watch FluGen President & CEO Paul Radspinner speak at the Jefferies 2021 Virtual Healthcare Conference
FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
(c)2016 FluGen, Inc. All rights reserved.
Twitter
Back to Top
FCOI policy
Comments are closed.